keyword
https://read.qxmd.com/read/38507239/use-of-crushed-tranexamic-acid-tablets-in-water-for-paediatric-patients-with-bleeding-disorders
#21
JOURNAL ARTICLE
Ahmad Al-Huniti, Linda Marshall, Dawn Rusk, Rajiv K Pruthi, Vilmarie Rodriguez, Asmaa Ferdjallah, Alexis Kuhn
BACKGROUND: Ε-Aminocaproic acid oral solution (EACA OS) is the only commercially available antifibrinolytic for patients who cannot swallow tablets. Insurance denials and high costs remain barriers to its use. OBJECTIVES: To determine the safety and efficacy of crushed tranexamic acid tablets in water (cTXAw) for children with bleeding disorders. METHODS: We retrospectively reviewed records of children (<10 years) with bleeding disorders who received cTXAw or EACA OS from 1 December 2018, through 31 July 2022, at Mayo Clinic (Rochester, Minnesota)...
March 20, 2024: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://read.qxmd.com/read/38505191/perioperative-treatment-with-rivaroxaban-and-dabigatran-on-changes-of-coagulation-and-platelet-activation-biomarkers-following-left-atrial-appendage-closure
#22
JOURNAL ARTICLE
Yao Yao, Yanli Li, Qinchun Jin, Xiaoye Li, Xiaochun Zhang, Qianzhou Lv
Insufficient data exist regarding the investigation of the impact of novel oral anticoagulants (NOACs) on coagulation activation biomarkers in the context of left atrial appendage closure (LAAC) and device-related thrombosis (DRT). The study was designed to investigate the changes and presence of coagulation activation biomarkers between different antithrombotic strategies following LAAC. A total of 120 nonvalvular atrial fibrillation patients intolerant of long-term anticoagulants, who underwent successful WATCHMAN closure implantation, were enrolled (rivaroxaban, n = 82; dabigatran, n = 38)...
2024: Cardiovascular Therapeutics
https://read.qxmd.com/read/38493932/vascular-study-of-decellularized-porcine-long-bones-characterization-of-a-tissue-engineering-model
#23
JOURNAL ARTICLE
R Evrard, J Manon, C Rafferty, L Fieve, O Cornu, T Kirchgesner, F E Lecouvet, T Schubert, B Lengele
INTRODUCTION: Massive bone allografts enable the reconstruction of critical bone defects in numerous conditions (e.g. tumoral, infection or trauma). Unfortunately, their biological integration remains insufficient and the reconstruction may suffer from several postoperative complications. Perfusion-decellularization emerges as a tissue engineering potential solution to enhance osseointegration. Therefore, an intrinsic vascular study of this novel tissue engineering tool becomes essential to understand its efficacy and applicability...
March 15, 2024: Bone
https://read.qxmd.com/read/38487818/impact-of-breastfeeding-duration-on-coagulation-in-women-with-and-without-history-of-gestational-diabetes-mellitus
#24
JOURNAL ARTICLE
Louise Fritsche, Dorina Löffler, Konstantinos Kantartzis, Gesine Flehmig, Michael Roden, Andreas Fritsche, Andreas L Birkenfeld, Andreas Peter, Martin Heni, Sebastian Hörber
OBJECTIVE: Breastfeeding is associated with a reduced maternal risk for cardiovascular diseases. Since the underlying mechanisms are still poorly understood, we here examined the impact of breastfeeding on the plasmatic coagulation system in women with and without history of gestational diabetes mellitus (GDM). METHODS: 76 participants of the German Gestational Diabetes Study (PREG; NCT04270578) were examined 14 [interquartile range: 12-26] months after delivery with a 5-point oral glucose tolerance test...
March 15, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38482706/von-willebrand-factor-for-outcome-prediction-within-different-clinical-stages-of-advanced-chronic-liver-disease
#25
JOURNAL ARTICLE
Nina Dominik, Bernhard Scheiner, Alberto Zanetto, Lorenz Balcar, Georg Semmler, Elena Campello, Michael Schwarz, Rafael Paternostro, Benedikt Simbrunner, Benedikt S Hofer, Albert Friedrich Stättermayer, Matthias Pinter, Michael Trauner, Peter Quehenberger, Paolo Simioni, Thomas Reiberger, Mattias Mandorfer
BACKGROUND AND AIMS: The prognostic performance of von Willebrand factor (VWF) may vary across clinical stages of advanced chronic liver disease (ACLD). Therefore, we investigated the evolution of VWF and other biomarkers throughout the full ACLD spectrum and evaluated their stage-specific prognostic utility. METHODS: We retrospectively included Viennese ACLD patients with available information on hepatic venous pressure gradient (HVPG), C-reactive protein (CRP)/VWF levels and outcomes...
March 14, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38481079/diagnosis-and-treatment-of-von-willebrand-disease-in-2024-and-beyond
#26
JOURNAL ARTICLE
Paula James, Frank Leebeek, Caterina Casari, David Lillicrap
MANUSCRIPT BACKGROUND AND AIM: The diagnosis and clinical care of patients with von Willebrand disease (VWD) has continued to evolve since the characterization of the von Willebrand factor (VWF) gene in 1985. This condition is almost certainly the most common inherited bleeding disorder, and the major symptomatic burden of the disease is experienced by females during their reproductive years. Diagnosis relies on the identification of a personal and family history of excessive mucocutaneous bleeding, and laboratory features consistent with quantitative and/or qualitative abnormalities of VWF...
March 13, 2024: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://read.qxmd.com/read/38479612/validation-of-baveno-vii-criteria-and-other-non-invasive-diagnostic-algorithms-for-clinically-significant-portal-hypertension-in-hepatitis-delta
#27
JOURNAL ARTICLE
Mathias Jachs, Lisa Sandmann, Lukas Hartl, Tammo Tergast, Michael Schwarz, David Josef Maria Bauer, Lorenz Balcar, Alena Ehrenbauer, Benedikt Silvester Hofer, Markus Cornberg, Henrike Lenzen, Katja Deterding, Michael Trauner, Mattias Mandorfer, Heiner Wedemeyer, Thomas Reiberger, Benjamin Maasoumy
BACKGROUND AND AIMS: Non-invasive tests (NIT) for clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) lack validation in patients infected with hepatitis D virus (HDV). METHODS: HDV-cACLD patients (LSM ≥10 kPa or histological METAVIR F3/F4 fibrosis) who underwent paired HVPG and NIT assessment at Medical University of Vienna or Hannover Medical School between 2013 and 2023 were retrospectively included...
March 11, 2024: Journal of Hepatology
https://read.qxmd.com/read/38477834/frequency-clinical-and-laboratory-findings-of-platelet-secretion-disorders-in-patients-referred-to-the-specialized-coagulation-laboratory-of-the-iranian-blood-transfusion-organization
#28
JOURNAL ARTICLE
Massoumeh Shahbazi, Minoo Ahmadinejad, Vahid Pirhajati Mahabadi, Amir Teimourpour, Khadijeh Golzadeh
OBJECTIVES: Platelet secretion disorders (PSDs) are a subgroup of platelet function disorders (PFDs) caused by defects in the content or release of platelet granules. These patients have a variable degree of mucocutaneous bleeding tendency. The diagnostic facilities of PSDs are imitated in Iran, even in specialized coagulation laboratories. The present study aims to estimate the frequency of PSDs among patients referred to the Iranian Blood Transfusion Organization (IBTO). METHODS: The research population includes all patients referred to the specialized coagulation laboratory of IBTO and requested platelet function and von Willebrand testing by their physicians...
March 12, 2024: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://read.qxmd.com/read/38473925/adamts-13-a-prognostic-biomarker-for-portal-vein-thrombosis-in-japanese-patients-with-liver-cirrhosis
#29
JOURNAL ARTICLE
Junya Suzuki, Tadashi Namisaki, Hiroaki Takya, Kosuke Kaji, Norihisa Nishimura, Akihiko Shibamoto, Shohei Asada, Takahiro Kubo, Satoshi Iwai, Fumimasa Tomooka, Soichi Takeda, Aritoshi Koizumi, Misako Tanaka, Takuya Matsuda, Takashi Inoue, Yuki Fujimoto, Yuki Tsuji, Yukihisa Fujinaga, Shinya Sato, Koh Kitagawa, Hideto Kawaratani, Takemi Akahane, Akira Mitoro, Masanori Matsumoto, Kiyoshi Asada, Hitoshi Yoshiji
Portal vein thrombosis (PVT), one of the most prevalent hepatic vascular conditions in patients with liver cirrhosis (LC), is associated with high mortality rates. An imbalance between a disintegrin-like metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS-13) enzyme and von Willebrand factor (VWF) is responsible for hypercoagulability, including spontaneous thrombus formation in blood vessels. Herein, we aimed to identify potential prognostic and diagnostic biomarkers in Japanese patients with LC and PVT...
February 26, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38467037/n-acetylcysteine-to-reduce-mortality-for-patients-requiring-cardiac-catheterization-or-cardiac-surgery-a-systematic-review-and-meta-analysis
#30
JOURNAL ARTICLE
Clement Gakuba, Alexandru-Daniel Dumitrascu, Pierre-Emmanuel Marson, Damien Legallois, Jean-Luc Hanouz, Denis Vivien, Sara Martinez De Lizarrondo, Maxime Gauberti, Damiano Cerasuolo
Multimers of von Willebrand factor (VWF) play a critical role in various processes inducing morbidity and mortality in cardiovascular risk patients. With the ability to reduce VWF multimers, N-acetylcysteine (NAC) could reduce mortality in patients undergoing coronary catheterization or cardiac surgery. However, its impact in perioperative period has never been studied so far in regard of its potential cardiovascular benefits. Then, four databases were searched for randomized controlled trials that compared in-hospital mortality between an experimental group, with NAC, and a control group without NAC, in patients undergoing coronary catheterization or cardiac surgery...
March 6, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38465770/elevated-factor-xi-is-associated-with-recurrent-left-ventricular-thrombus-of-unknown-origin
#31
JOURNAL ARTICLE
Łukasz Zandecki, Michał Ząbczyk, Anetta Undas
BACKGROUND: Elevated factor XI (FXI) has been shown to predispose to thromboembolism. We investigated whether it is associated with left ventricular thrombus (LVT) formation, its recurrence and subsequent thromboembolic events. METHODS: In 54 patients with prior LVT of unknown origin, who stopped anticoagulation and 54 controls, we determined FXI, along with plasma clot permeability (Ks ), fibrinolysis time (CLT), endogenous thrombin potential (ETP), von Willebrand factor (vWF) and fibrinolysis proteins...
March 11, 2024: European Journal of Clinical Investigation
https://read.qxmd.com/read/38463081/knee-replacement-surgery-in-a-patient-with-acquired-von-willebrand-disease-a-case-study-with-recommendations-for-patient-management
#32
María Teresa Álvarez Román, María Isabel Rivas Pollmar, Hortensia De la Corte-Rodríguez, Primitivo Gómez-Cardero, E Carlos Rodríguez-Merchán, Mar Gutiérrez-Alvariño, Eduardo García-Pérez, Mónica Martín-Salces, Damaris Zagrean, Nora V Butta-Coll, Víctor Jiménez-Yuste
INTRODUCTION AND IMPORTANCE: Acquired von Willebrand disease (AvWD) is a rare underdiagnosed bleeding disorder caused by alterations in the levels of the major blood-clotting protein von Willebrand factor (vWF). The clinical and laboratory parameters of AvWD are similar to congenital vWD, but it is found in individuals with no positive family history with no underlying genetic basis. The disease remains multifactorial and incompletely understood. Proposed mechanisms include the development of autoantibodies to vWF, absorption of high molecular weight vWF multimers that impair normal function, shear stress induced vWF cleavage and increased proteolysis...
March 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38462793/diagnosis-and-treatment-challenges-in-lower-resource-countries-state-of-the-art
#33
JOURNAL ARTICLE
Johnny Mahlangu, Saliou Diop, Michelle Lavin
The 2022 World Federation of Haemophilia Annual Global Survey (AGS) reports that 454,690 patients with inherited bleeding disorders (IBD) have been identified globally. While this represents noteworthy progress, haemophilia epidemiology data indicate that 75% of people with inherited bleeding disorders living in low-income and low-to-middle-income countries have yet to be diagnosed. The AGS also revealed that 11 billion clotting factor units are available to treat haemophilia A and B globally. Due to a lack of finance, these treatments are unavailable to haemophilia in low-income countries with a consequence lack of access equity for haemophilia treatment in these communities...
March 10, 2024: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://read.qxmd.com/read/38462141/outcomes-following-total-hip-arthroplasty-in-patients-who-have-von-willebrand-disease-depend-on-postoperative-anticoagulation
#34
JOURNAL ARTICLE
Will Jiang, Joshua Sanchez, Meera M Dhodapkar, Zachary J Radford, Lee E Rubin, Jonathan N Grauer
BACKGROUND: Von Willebrand disease (VWD) is the most common congenital bleeding disorder. This autosomal dominant condition arises from quantitative or qualitative defects of Von Willebrand factor. To our knowledge, this study leveraged a national database to characterize the largest VWD cohort of total hip arthroplasty (THA) patients to date, assessing 90-day postoperative adverse events and 5-year revision-free survival. METHODS: Adult patients who underwent primary THA for osteoarthritis were identified from January 2010 to October 2021 in a nationwide database...
March 8, 2024: Journal of Arthroplasty
https://read.qxmd.com/read/38461614/impact-of-allele-selective-silencing-of-von-willebrand-factor-in-mice-based-on-a-single-nucleotide-allelic-difference-in-von-willebrand-factor
#35
JOURNAL ARTICLE
Yvonne K Jongejan, Noa A Linthorst, Elisa Schrader Echeverri, Sebastiaan N J Laan, Richard J Dirven, James E Dahlman, Bart J M van Vlijmen, Cécile V Denis, Jeroen C J Eikenboom
INTRODUCTION: Von Willebrand factor (VWF) plays a pathophysiological role in hemostatic disorders. Partial inhibition of the VWF gene through small interfering RNA (siRNA)-mediated allele-selective silencing could be a promising therapeutic strategy. For von Willebrand disease, allele-selectively inhibiting dominant-negative VWF-alleles might ameliorate the phenotype. For thrombotic disorders, partial VWF reduction can lower thrombotic risk, while avoiding bleeding. Previously, we demonstrated the feasibility of Vwf-silencing in homozygous C57BL/6J (B6) or 129S1/SvImJ (129S) mice...
March 5, 2024: Thrombosis Research
https://read.qxmd.com/read/38454378/high-thrombin-activatable-fibrinolysis-inhibitor-expression-in-thrombi-from-stroke-patients-in-elevated-estrogen-states
#36
JOURNAL ARTICLE
Tamanna Agarwal, Oana Madalina Mereuta, Sherief Ghozy, Jorge L Arturo Larco, Cem Bilgin, Ram Kadirvel, Waleed Brinjikji, David F Kallmes
BACKGROUND: The risk of acute ischemic stroke (AIS) associated with high estrogen states, including pregnant patients and those using oral contraceptives, has been well documented. We described the histological composition of thrombi collected in these cases. METHODS: From a prospective tissue registry (STRIP registry) of thrombi retrieved during mechanical thrombectomy for AIS, we identified 5 patients with high estrogen states: 1 post-partum patient, 1 undergoing hormone replacement therapy and 3 consuming oral contraceptive pills...
March 7, 2024: BMC Neurology
https://read.qxmd.com/read/38454298/how-to-investigate-mild-to-moderate-bleeding-disorders-and-bleeding-disorder-of-unknown-cause
#37
REVIEW
Alessandro Casini, Johanna Gebhart
A bleeding tendency is one of the most common complaints observed by hematologists. It is challenging to differentiate a clinically insignificant bleeding from a bleeding phenotype that requires hemostatic evaluation and medical intervention. A thorough review of personal and familial history, objective assessment of bleeding severity using a bleeding assessment tool, and a focused physical examination are critical to correctly identifying suspected patients with mild to moderate bleeding disorders (MBDs). A basic laboratory work-up should be performed in all patients referred for a bleeding tendency...
March 7, 2024: International Journal of Laboratory Hematology
https://read.qxmd.com/read/38453024/mental-health-in-persons-with-von-willebrand-disease-in-the-united-states-a-large-national-database-study
#38
JOURNAL ARTICLE
Andrew Tran, Emily Waller, Joana M Mack, Shelley E Crary, Divyaswathi Citla-Sridhar
BACKGROUND: There are very few large population-based studies studying mental health in persons with von Willebrand disease (PwvWD). OBJECTIVES: We aim to assess prevalence of depression and anxiety in PwvWD over a period of 20 years and identify bleeding symptoms that may be more likely associated with depression and anxiety in PwvWD. METHODS: This is a retrospective cohort study using a de-identified national dataset from 1,118 hospitals with 176 million patients...
March 5, 2024: Journal of Thrombosis and Haemostasis: JTH
https://read.qxmd.com/read/38447034/simple-blood-tests-to-diagnose-compensated-advanced-chronic-liver-disease-and-stratify-risk-of-clinically-significant-portal-hypertension
#39
JOURNAL ARTICLE
Georg Semmler, Lukas Hartl, Yuly Paulin Mendoza, Benedikt Simbrunner, Mathias Jachs, Lorenz Balcar, Michael Schwarz, Benedikt Silvester Hofer, Laurenz Fritz, Anna Schedlbauer, Katharina Stopfer, Daniela Neumayer, Jurij Maurer, Robin Szymanski, Elias Laurin Meyer, Bernhard Scheiner, Peter Quehenberger, Michael Trauner, Elmar Aigner, Annalisa Berzigotti, Thomas Reiberger, Mattias Mandorfer
BACKGROUND AIMS: Compensated advanced chronic liver disease (cACLD) identifies patients at risk for clinically significant portal hypertension (CSPH), and thus, for liver-related complications. Limited availability of liver stiffness measurements (LSM) impedes the identification of patients at risk for cACLD/CSPH outside of specialized clinics. We aimed to develop a blood-based algorithm to identify cACLD by FIB-4 and CSPH by von Willebrand factor/platelet count ratio (VITRO). APPROACH RESULTS: Patients with (suspected) compensated chronic liver disease undergoing FIB4+LSM were included in the LSM/FIB-4-cohorts from Vienna&Salzburg...
March 6, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38441385/self-assembled-dna-composite-engineered-mesenchymal-stem-cells-for-improved-skin-wound-repair
#40
JOURNAL ARTICLE
Zhuoting Li, Yiming Wang, Hong Wang, Haiyan Wang, Yingxu Shang, Shihua Wang, Qin Han, Jing Li, Robert Chunhua Zhao, Qiao Jiang, Baoquan Ding
The direct use of mesenchymal stem cells (MSCs) as therapeutics for skin injuries is a promising approach, yet it still faces several obstacles, including limited adhesion, retention, and engraftment of stem cells in the wound area, as well as impaired regenerative and healing functions. Here, DNA-based self-assembled composites are reported that can aid the adhesion of MSCs in skin wounds, enhance MSC viability, and accelerate wound closure and re-epithelialization. Rolling-circle amplification (RCA)-derived DNA flowers, equipped with multiple copies of cyclic Arg-Gly-Asp (cRGD) peptides and anti-von Willebrand factor (vWF) aptamers, act as robust scavengers of reactive oxygen species (ROS) and enable synergistic recognition and adhesion to stem cells and damaged vascular endothelial cells...
March 5, 2024: Small
keyword
keyword
16647
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.